ISOVUE® (iopamidol injection)


Trust experience, choose confidence 1, 2, 3


Bracco was proud to launch the first ready-to-use non-ionic contrast agent, Isovue®, in 1981. This agent helped consolidate Bracco, as a global leader in the X-Ray contrast media market and research. Since the launch of Isovue® in 1981 many other non-ionic compounds have been made available, however, Isovue® remains the non-ionic agent of choice for thousands of clinicians world-wide. Isovue® is sold in more than 80 countries through affiliates, partners, distributors and licensees 1.

Its long history and unique physicochemical properties 2 have gained Isovue® many unique distinctions, including:


  • The first ready-to-use non-ionic agent with the 370 mg/mL concentration 1
  • The subject of over 2000 scientific publications 3
  • Administered in over 400 million doses 1
  • Approved in a wide range of indications (including pediatric), concentrations and volumes 2
  • A proven safety profile 4, 5
  • The advent of MDCT and new CT applications (cardiac, vascular, perfusion, etc) required clinicians to adjust their contrast protocols in particular in terms of volume, concentration and administration rate. Many renowned experts strongly promote the use of high concentration non-ionic agents in an effort to best exploit contrast utilization 6. The use of high concentration best matches the speed and power of multi-slice scanners, providing earlier, higher and shorter enhancement peak.
  • Furthermore, Isovue® has proven to be well tolerated in many study cohorts. In particular, in renally-impaired patients. Two large comparative studies show that the risk of CIN (Contrast Induced Nephropathy), when the highly concentrated Iopamiro-370 is used in CT or during catheter endovascular procedures even in a subset of patients with diabetes, is not statistically different from that of iodixanol-320 4, 5, which provides inferior enhancement in first pass MDCT 7.
  • The efficacy of high iodine concentration and the positive results even in patients at risk of developing CIN make Isovue® particularly indicated also for intra-arterial use in angiography and cardiangiography procedures where the volume of contrast and the risk of renal complications are highest 5

Contact us

Please fill out the form below and we will get back to you.

Différents pays peuvent avoir mis en place des processus spécifiques pour traiter les signalements d’effets indésirables. Pour signaler un effet indésirable lié aux produits Bracco, vous pouvez trouver des contacts spécifiques et des informations en sélectionnant la page "Pharmacovigilance" de votre pays.

* En cochant cette case et en cliquant sur le bouton Soumettre de cette page, je certifie que je suis un professionnel de santé et autorise Bracco Imaging S.p.A., ou des parties agissant en son nom, à me contacter pour me fournir des informations concernant Bracco Imaging S.p.A., les produits et solutions, les invitations à des événements et des séminaires, les mises à jour du secteur et d’autres notifications. Je comprends que les informations que je fournis ne seront pas transmises à quiconque en dehors de Bracco Imaging S.p.A., à l’exception des agents ou représentants qui traitent cette demande.



For any product or type of product, whether a drug or device, referenced in this website, physicians should carefully review the product's package insert, instructions for use, or user manual prior to patient administration to ensure proper utilization of the product. The Core Summaries of Product Characteristics for the main Bracco Imaging products are available on line, however; please consult your full locally approved information prior to administration.